ATE515499T1 - Neue kristallform von 5-hydroxy-1-methylhydantoin - Google Patents

Neue kristallform von 5-hydroxy-1-methylhydantoin

Info

Publication number
ATE515499T1
ATE515499T1 AT03745985T AT03745985T ATE515499T1 AT E515499 T1 ATE515499 T1 AT E515499T1 AT 03745985 T AT03745985 T AT 03745985T AT 03745985 T AT03745985 T AT 03745985T AT E515499 T1 ATE515499 T1 AT E515499T1
Authority
AT
Austria
Prior art keywords
methylhydantoin
hydroxy
crystal form
new crystal
new
Prior art date
Application number
AT03745985T
Other languages
English (en)
Inventor
Kaoru Okamoto
Naoharu Nishimura
Akira Ishii
Original Assignee
Nippon Zoki Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co filed Critical Nippon Zoki Pharmaceutical Co
Application granted granted Critical
Publication of ATE515499T1 publication Critical patent/ATE515499T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
AT03745985T 2002-04-10 2003-04-09 Neue kristallform von 5-hydroxy-1-methylhydantoin ATE515499T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002107533 2002-04-10
PCT/JP2003/004497 WO2003084934A1 (en) 2002-04-10 2003-04-09 Novel crystal form of 5-hydroxy-1-methylhydantoin

Publications (1)

Publication Number Publication Date
ATE515499T1 true ATE515499T1 (de) 2011-07-15

Family

ID=28786466

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08015840T ATE536346T1 (de) 2002-04-10 2003-04-09 Verfahren zur herstellung der verbindung 5- hydroxy-1-methylhydantoin
AT03745985T ATE515499T1 (de) 2002-04-10 2003-04-09 Neue kristallform von 5-hydroxy-1-methylhydantoin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08015840T ATE536346T1 (de) 2002-04-10 2003-04-09 Verfahren zur herstellung der verbindung 5- hydroxy-1-methylhydantoin

Country Status (12)

Country Link
US (2) US7569701B2 (de)
EP (2) EP1493734B1 (de)
JP (3) JP4347598B2 (de)
KR (2) KR20040099357A (de)
CN (1) CN1291978C (de)
AT (2) ATE536346T1 (de)
AU (2) AU2003236013B2 (de)
CA (2) CA2700679C (de)
DK (2) DK1493734T3 (de)
ES (2) ES2377583T3 (de)
TW (1) TWI353979B (de)
WO (1) WO2003084934A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
US20060241162A1 (en) * 2005-04-20 2006-10-26 Kaoru Okamoto Optically active (R)-hydantoin derivative
US20060241163A1 (en) * 2005-04-20 2006-10-26 Kaoru Okamoto Optically active (S)-hydantoin derivative
CN101325952B (zh) * 2005-12-16 2012-02-08 株式会社三和化学研究所 用于急性肾衰竭的预防和治疗剂
JP5546198B2 (ja) 2009-10-09 2014-07-09 キヤノン株式会社 固体撮像装置
WO2015129750A1 (ja) 2014-02-26 2015-09-03 日本臓器製薬株式会社 慢性腎臓病の進行抑制又は改善剤
WO2023277521A1 (ko) * 2021-07-02 2023-01-05 주식회사 경보제약 ５－히드록시－１－메틸이미다졸리딘－２，４－디온 화합물을 유효성분으로 포함하는 동물용 약학적 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS554305A (en) 1978-06-13 1980-01-12 Nippon Zoki Pharmaceut Co Ltd Remedy for disease caused by stress and its preparation
JPH0238588B2 (ja) 1981-01-06 1990-08-31 Nippon Zoki Pharmaceutical Co Shinkihidantoinkagobutsu
JPH062748B2 (ja) 1984-03-08 1994-01-12 日本臓器製薬株式会社 新規ヒダントイン誘導体及び該化合物を有効成分として含有する医薬組成物
AU578068B2 (en) * 1984-03-08 1988-10-13 Nippon Zoki Pharmaceutical Co., Ltd. Hydantoin derivatives and pharmaceutical compositions containing them
JPH0686436B2 (ja) 1984-11-15 1994-11-02 日本臓器製薬株式会社 新規ヒダントイン誘導体及び該化合物を含有する医薬組成物
JPS6143168A (ja) 1984-08-06 1986-03-01 Showa Denko Kk ヒダントインの製造方法
JPS61211567A (ja) 1985-03-18 1986-09-19 Hitachi Electronics Eng Co Ltd ボ−ルネジ・ナツト支承装置
JPS61212567A (ja) 1985-03-18 1986-09-20 Showa Denko Kk ヒダントイン製造における着色防止法
JPH0623102B2 (ja) 1985-08-22 1994-03-30 日本臓器製薬株式会社 脂質低下剤
HU196775B (en) 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
ZA885709B (en) 1987-08-19 1989-04-26 Fujisawa Pharmaceutical Co Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid(syn isomer)
JPS6475473A (en) * 1987-09-17 1989-03-22 Nippon Zoki Pharmaceutical Co Production of hydantoin derivative
JPH01299276A (ja) 1988-05-26 1989-12-04 Nippon Zoki Pharmaceut Co Ltd ヒダントイン誘導体の製造方法
JP2544183B2 (ja) 1988-07-29 1996-10-16 日本臓器製薬株式会社 新規パラバン酸誘導体及び該化合物を有効成分として含有する医薬組成物
JP2678499B2 (ja) 1989-08-09 1997-11-17 日本臓器製薬 株式会社 尿毒症毒素低下剤
GB9027018D0 (en) 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
JPH04342556A (ja) 1991-01-23 1992-11-30 Nitto Chem Ind Co Ltd テトラシアノキノジメタン複塩とその製法
GB9119001D0 (en) 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
US5294615A (en) 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
US5412095A (en) 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
JP3259476B2 (ja) * 1993-09-30 2002-02-25 日本ゼオン株式会社 シクロオレフィン系開環重合体水素添加物の製造方法
JPH07149732A (ja) 1993-10-06 1995-06-13 Showa Denko Kk ５−アリールヒダントイン化合物およびその誘導体の製造方法
US5681843A (en) 1994-12-20 1997-10-28 Nippon Zoki Pharmaceutical Co., Ltd. Parabanic acid derivatives
JPH08269018A (ja) 1995-03-31 1996-10-15 Showa Denko Kk ５−置換ヒダントイン化合物の製造方法
JP3072463B2 (ja) 1995-06-19 2000-07-31 日進医療器株式会社 起立用車椅子
JP3836203B2 (ja) 1995-12-20 2006-10-25 日本臓器製薬株式会社 活性酸素・フリーラジカル消去剤
US6197806B1 (en) 1995-12-20 2001-03-06 Nippon Zoki Pharmaceutical Co., Ltd. Eliminating agent for activated oxygen and free radicals
JPH1072446A (ja) 1996-06-24 1998-03-17 Sumitomo Chem Co Ltd １−置換−ヒダントイン類の製造法
JPH10182460A (ja) 1996-12-27 1998-07-07 Nippon Zoki Pharmaceut Co Ltd ３−デオキシグルコソン生成阻害剤
JP2000031488A (ja) * 1997-08-26 2000-01-28 Semiconductor Energy Lab Co Ltd 半導体装置およびその作製方法
JPH11171843A (ja) 1997-11-18 1999-06-29 Mitsubishi Rayon Co Ltd 嵩密度の大きい［ｓ，ｓ］−エチレンジアミン−ｎ，ｎ’−ジコハク酸の結晶およびその取得方法
AU754989B2 (en) 1998-11-16 2002-11-28 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for intractable vasculitis
JP4374407B2 (ja) * 1998-11-27 2009-12-02 財団法人相模中央化学研究所 ３−イソクロマノン誘導体を製造する方法
JP4711523B2 (ja) 2001-02-13 2011-06-29 日本臓器製薬株式会社 低アルブミン血症改善剤
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
JP2004123736A (ja) 2002-09-11 2004-04-22 Nippon Zoki Pharmaceut Co Ltd 光学活性（ｒ）−ヒダントイン誘導体
JP2004123735A (ja) 2002-09-11 2004-04-22 Nippon Zoki Pharmaceut Co Ltd 光学活性（ｓ）−ヒダントイン誘導体
DE102004005179B4 (de) 2004-02-02 2006-07-13 Wobben, Aloys, Dipl.-Ing. Windenergieanlage
US20060241163A1 (en) 2005-04-20 2006-10-26 Kaoru Okamoto Optically active (S)-hydantoin derivative
US20060241162A1 (en) 2005-04-20 2006-10-26 Kaoru Okamoto Optically active (R)-hydantoin derivative

Also Published As

Publication number Publication date
JP2008266353A (ja) 2008-11-06
EP1493734A4 (de) 2006-07-05
CA2479549C (en) 2012-06-12
EP1493734A1 (de) 2005-01-05
WO2003084934A1 (en) 2003-10-16
CA2479549A1 (en) 2003-10-16
DK2003122T3 (da) 2012-02-20
TW200306307A (en) 2003-11-16
EP1493734B1 (de) 2011-07-06
EP2003122A2 (de) 2008-12-17
AU2009208156B2 (en) 2012-01-19
JP5202129B2 (ja) 2013-06-05
ES2377583T3 (es) 2012-03-29
CN1291978C (zh) 2006-12-27
US20090270634A1 (en) 2009-10-29
AU2003236013A1 (en) 2003-10-20
US7569701B2 (en) 2009-08-04
KR101071796B1 (ko) 2011-10-11
KR20090091366A (ko) 2009-08-27
ATE536346T1 (de) 2011-12-15
EP2003122A3 (de) 2009-01-07
JP4347598B2 (ja) 2009-10-21
US20050143437A1 (en) 2005-06-30
AU2009208156A1 (en) 2009-09-03
CA2700679C (en) 2012-09-04
CN1646498A (zh) 2005-07-27
TWI353979B (en) 2011-12-11
KR20040099357A (ko) 2004-11-26
CA2700679A1 (en) 2003-10-16
EP2003122B1 (de) 2011-12-07
ES2367483T3 (es) 2011-11-03
JP2004002376A (ja) 2004-01-08
DK1493734T3 (da) 2011-10-03
AU2003236013B2 (en) 2009-05-28
JP2009235088A (ja) 2009-10-15
US7858806B2 (en) 2010-12-28

Similar Documents

Publication Publication Date Title
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
MY147435A (en) Process for the production of atorvastatin calcium in amorphous form
EP1484384A4 (de) Verfahren zur herstellung von biokraftstoff
FI20021899A0 (fi) Menetelmä kuitutuotteen valmistamiseksi
CY1109648T1 (el) Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αγωγη εγκεφαλικου επεισοδιου
FR2844277B1 (fr) Bacterie produisant un l-aminoacide et procede de production de ce l-aminoacide
ATE291024T1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
EP1538190A4 (de) Hochbrillianter mechanolumineszenzstoff und verfahren zu seiner herstellung
PT1129066E (pt) Producao de 2-amino-2-[2-(4-c2-20-alquil-fenil)etil]propano-1,3-diois
MXPA03004986A (es) Proceso para preparar polimeros de emulsion con alta pureza.
EP1514870A4 (de) Prodrug und verfahren zu deren herstellung
EP1544275A4 (de) Mechanolumineszenzstoff und dessen herstellung
DK1493734T3 (da) Ny krystalform af 5-hydroxy-1-methylhydantoin
EP1574532A4 (de) Polychloroprenlatex, herstellungsverfahren dafür und wässrige klebstoffzusammensetzungen
FI20000867A0 (fi) Menetelmä klooridioksidin valmistamiseksi eri pelkistimien yhteiskäytöllä
DE60200535D1 (de) Verfahren zur Herstellung von hoch reinem Pemirolast
ITBO20020312A0 (it) Macchina per la realizzazione di fustellati di cartone
BR0308042B8 (pt) processo para a produÇço de um carboxilato de alquenila ou de um carboxilato de alquila.
IS7373A (is) Aðferð til framleiðslu á flútikasón própíónati, einkum á fjölbreytilegu formi 1
FR2833272B1 (fr) Nouvelles phytases et procede de production de ces phytases
EP1496115A4 (de) Verfahren zur herstellung von canthaxanthin
EP1375502A4 (de) Verfahren zur produktion von 2,6-dihalogenopurinen
BR0318252B1 (pt) processo de produzir um material laminado de embalagem.
ATE335766T1 (de) Antikörper gegen caspase-8, ihre herstellung und verwendung
EP1486529A4 (de) Verfahren zur herstellung eines thermoplastharzfilms

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties